SUBSCRIBE
SUBSCRIBE

Abide Therapeutics

NEWS
Abide Therapeutics was acquired by Lundbeck in 2019.
Deals
Lundbeck Acquires Abide Therapeutics for $250M, Gains San Diego Discovery Site
With a $250 million cash down payment, Denmark’s H. Lundbeck A/S snapped up San Diego-based Abide Therapeutics to gain a novel discovery platform and a U.S.-based research hub.
May 6, 2019
 · 
2 min read
 · 
Alex Keown
IN THE PRESS
Drug Development
Abide Therapeutics Announces First Subject Dosed In PET Occupancy Study with [18F]ABX-1488, A Proprietary Human Monoacylglycerol Lipase (MGLL)-Specific PET Ligand
May 10, 2016
 · 
3 min read
Drug Development
Abide Therapeutics Appoints Richard N. Kender To Board Of Directors
January 19, 2016
 · 
3 min read
Business
Abide Therapeutics Appoints Dr. Chan Beals As Chief Medical Officer
January 6, 2016
 · 
3 min read
Drug Development
Abide Therapeutics Appoints Donald Hertzog As Vice President, Early Lead Identification
September 8, 2015
 · 
3 min read
Drug Development
Abide Therapeutics Announces First Subject Dosed In First-In-Human Clinical Study Of ABX-1431, An Investigational Endocannabinoid System Modulator
July 7, 2015
 · 
4 min read
Business
Abide Therapeutics Announces A Collaborative Agreement With The University of Oxford
November 4, 2014
 · 
3 min read
Business
Abide Therapeutics Appoints Nancy Thornberry To Board Of Directors
July 29, 2014
 · 
3 min read
Business
San Diego Startup Abide Therapeutics Strikes Immune Disorder Pact With Celgene, Financial Details Undisclosed
February 28, 2014
 · 
3 min read
Load More
AWARDS
  • NextGen Class of 2015
JOBS